Further analysis revealed significantly reduced percentages of CD159a/NKG2A+ CD56dim and CD56brightNK-cells within tumor tissue when compared to peripheral blood of GBM patients, whereas the percentages of CD158a/KIR2DL-1+ and CD158b/KIR2DL-2/3+ CD56dim and CD56bright NK-cells were not different (Fig. 1b). This evidence concerns the gene KIR2DL3 and glioblastoma.